Screened 2026-09-07 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Glass House Brands Inc. holds its Accumulation at $11.81. Consolidating, no directional conviction, held for 26 days.
As held on the ledger · 2026-09-07
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 26 days
Price at the screen
$11.81
Valuation
N/A trailing · 44.57 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.51
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
10.02%
Below 33%
Interest-bearing debt is just 10.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
2.61%
Below 33%
Cash held in interest-bearing accounts and securities is 2.6% of assets, under the one-third limit.
Pass
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads FAIR VALUE: it trades above our $9.19 fair value estimate.
Fair value range in USD, drawn from the 2026-09-07 screen. The gold marker is the market price at the same screen. The price runs 22.2% above the base estimate.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-07 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cannabis Shops Still Deep in the Red
Picture a grower running its own stores and selling bulk flower to other retailers, yet still reporting revenue down 10 percent and a 21 percent loss margin. Glass House trades at 44.6 times forward earnings with return on equity at minus 20 percent, well above our fair value of 9.19 against the current 11.81 price. The ethical screen clears it, but the numbers show a business that has not yet turned consistent cash.
The two-analyst median target of 16 sits even higher, yet offers little comfort when growth is negative and the company remains unprofitable. A premium multiple on shrinking sales rarely ends well in a market this fragmented and heavily regulated.
Margins stay thin while competition and state rules keep shifting, so any rebound in volumes could vanish quickly. The current price leaves no margin of safety. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GLASF trades on OQX. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-30Accumulation$11.81+0.0%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (2 analysts) rates it buy, with a mean price target of $10.
2026-07-31Accumulation$11.81-10.9%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 10.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (2 analysts) rates it buy, with a mean price target of $10.
2026-07-18Accumulation$13.25+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 33% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 137%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (2 analysts) rates it buy, with a mean price target of $10.
2026-07-03Accumulation$13.25+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$13.25Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
